Literature DB >> 34052879

Why so few Nobel Prizes for cancer researchers? An analysis of Nobel Prize nominations for German physicians with a focus on Ernst von Leyden and Karl Heinrich Bauer.

Nils Hansson1, Giacomo Padrini2, Friedrich H Moll2, Thorsten Halling2, Carsten Timmermann3.   

Abstract

PURPOSE: To date, 11 scientists have received the Nobel Prize for discoveries directly related to cancer research. This article provides an overview of cancer researchers nominated for the Nobel Prize from 1901 to 1960 with a focus on Ernst von Leyden (1832-1910), the founder of this journal, and Karl Heinrich Bauer (1890-1978).
METHODS: We collected nominations and evaluations in the archive of the Nobel committee of physiology or medicine in Sweden to identify research trends and to analyse oncology in a Nobel Prize context.
RESULTS: We found a total of 54 nominations citing work on cancer as motivation for 11 candidates based in Germany from 1901 to 1953. In the 1930s, the US became the leading nation of cancer research in a Nobel context with nominees like Harvey Cushing (1869-1939) and George N. Papanicolaou (1883-1962). DISCUSSION: The will of Alfred Nobel stipulates that Nobel laureates should have "conferred the greatest benefit to mankind". Why were then so few cancer researchers recognized with the Nobel medal from 1901 to 1960? Our analysis of the Nobel dossiers points at multiple reasons: (1) Many of the proposed cancer researchers were surgeons, and surgery has a weak track record in a Nobel context; (2) several scholars were put forward for clinical work and not for basic research (historically, the Nobel committee has favoured basic researchers); (3) the scientists were usually not nominated for a single discovery, but rather for a wide range of different achievements.

Entities:  

Keywords:  Ernst von Leyden; Excellence in cancer research; Karl Heinrich Bauer; Leonell Strong; Nobel Prize

Year:  2021        PMID: 34052879     DOI: 10.1007/s00432-021-03671-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  4 in total

1.  [Karl Sudhoff and the Nobel Prize].

Authors:  Nils Hansson
Journal:  Medizinhist J       Date:  2015

Review 2.  J. Mikulicz-Radecki, K. H. Bauer, and W. Bross. Three great surgeons, three different epochs, one clinic in Wroclaw.

Authors:  Wojciech Anatol Kustrzycki
Journal:  Thorac Cardiovasc Surg       Date:  2012-12-04       Impact factor: 1.827

3.  The "Nobel Population" in Pharmacology: Nobel Prize laureates, nominees and nominators 1901-1953 with a focus on B. Naunyn and O. Schmiedeberg.

Authors:  Michael Pohar; Nils Hansson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-18       Impact factor: 3.000

4.  Who is who in cardiovascular research? What a review of Nobel Prize nominations reveals about scientific trends.

Authors:  Marie Drobietz; Adrian Loerbroks; Nils Hansson
Journal:  Clin Res Cardiol       Date:  2021-03-06       Impact factor: 5.460

  4 in total
  1 in total

1.  Ernst von Leyden (1832-1910): a pioneer in making oncology a respected medical discipline.

Authors:  Peter Voswinckel; Nils Hansson
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-21       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.